SBIR grant awarded to develop therapy for alcoholic liver disease-associated hepatorenal syndrome

The Institute of Human Virology (IHV) on the College of Maryland Faculty of Medication (UMSOM) and MitoPower LLC (“MitoPower”) had been awarded an SBIR (Small Enterprise Innovation Analysis) grant of as much as $6.5 million over 5 years from the Nationwide Institutes of Well being’s Nationwide Institute on Alcohol Abuse and Alcoholism. The funds will help the event of MitoPower’s lead compound, MP-04, for the therapy of kidney dysfunction on account of alcoholic liver illness, a situation often called alcoholic liver disease-associated hepatorenal syndrome (HRS). The IHV, a Heart of Excellence of the International Virus Community (GVN), will conduct first-in-human single and a number of ascending dose research to check the security of the compound, adopted by a Section 1b examine in sufferers.

There are not any present therapeutic choices that particularly tackle the mobile dysfunction and systemic inflammatory response that contribute to the extreme impairment of liver and kidney operate and progressive organ failure in sufferers with extreme alcoholic hepatitis. We’re working to finish IND-enabling research for MP-04 and are excited to collaborate with IHV to characterize this promising compound in human research.”

Mani Subramanian, MD, PhD and CEO of MitoPower

Greater than 250,000 hospitalizations every year within the U.S. are on account of issues of alcoholic liver illness. HRS is an acute complication of cirrhosis (liver scarring) or a extreme alcoholic hepatitis (liver irritation) progressive situation resulting in kidney failure. HRS is related to mortality charges reaching 50%, with many sufferers requiring invasive remedies akin to dialysis and/or liver transplant.

“There’s an pressing, unmet want for an efficient remedy to deal with HRS attributable to extreme alcoholic hepatitis and cirrhosis. Globally, the incidence and prevalence of alcoholic liver illness continues to extend and stays a big reason for liver failure and liver transplantation,” mentioned Prof. Shyam Kottilil, MBBS, PhD, Professor of Medication and Director of the Division of Scientific Care and Analysis, Institute of Human Virology on the College of Maryland Faculty of Medication, and senior advisor to the International Virus Community (GVN). “MP-04 is a novel therapeutic that has proven promise in preclinical research to reverse organ dysfunction and systemic inflammatory response syndrome (SIRS) that holds promise in doubtlessly reversing HRS.”

The Theodore E. Woodward Chair in Medication Stephen N. Davis, MBBS, FRCP, FACE, MACP, mentioned, “We’re honored to associate educational analysis with business to develop therapies that enhance our sufferers’ well being and high quality of life, particularly for continual illnesses for which we’ve no identified remedies.”

UMSOM Dean E. Albert Reece, MD, PhD, MBA, Government Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko Okay. Bowers Distinguished Professor, mentioned, “HRS impacts many Native American and Alaskan Natives disproportionately, and Black and Mexican Individuals usually tend to endure worse outcomes. Growing an efficient therapy would be the first step to find a option to tackle these disparities.”

Robert Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medication, Co-Founder & Director of the Institute of Human Virology at UMSOM, and Co-Founder and Worldwide Scientific Director of the International Virus Community (GVN), mentioned, “The Institute is happy to see our Scientific Trials Unit’s portfolio proceed to develop underneath the terrific management of Professor Kottilil. Whereas we proceed to deal with therapeutics for viruses akin to HIV and SARS-CoV-2, it’s also essential that we analysis improvements that may fight devastating continual diseases, akin to liver illness and kidney dysfunction.”

This award was granted by the Nationwide Institutes of Well being underneath Award Quantity U44 AA029833. The content material of this press launch is solely the duty of the writer and doesn’t essentially characterize the official views of the NIH.


College of Maryland Faculty of Medication

#SBIR #grant #awarded #develop #therapy #alcoholic #liver #diseaseassociated #hepatorenal #syndrome